Drug Price Trends for NDC 00173-0876

Average Pharmacy Cost for 00173-0876

Drug Name	NDC	Price/Unit ($)	Unit	Date
ARNUITY ELLIPTA 200 MCG INH	00173-0876-14	8.89214	EACH	2026-03-18
ARNUITY ELLIPTA 200 MCG INH	00173-0876-10	8.89863	EACH	2026-03-18
ARNUITY ELLIPTA 200 MCG INH	00173-0876-14	8.89214	EACH	2026-02-18
ARNUITY ELLIPTA 200 MCG INH	00173-0876-10	8.89875	EACH	2026-02-18
ARNUITY ELLIPTA 200 MCG INH	00173-0876-14	8.89214	EACH	2026-01-21

Best Wholesale Price for NDC 00173-0876

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ARNUITY ELLIPTA 200MCG	GlaxoSmithKline	00173-0876-10	30	179.60	5.98667	2022-08-01 - 2027-07-31	Big4
ARNUITY ELLIPTA 200MCG	GlaxoSmithKline	00173-0876-10	30	194.56	6.48533	2022-08-01 - 2027-07-31	FSS
ARNUITY ELLIPTA 200MCG	GlaxoSmithKline	00173-0876-10	30	187.46	6.24867	2023-01-01 - 2027-07-31	Big4
ARNUITY ELLIPTA 200MCG	GlaxoSmithKline	00173-0876-10	30	210.12	7.00400	2023-01-01 - 2027-07-31	FSS
ARNUITY ELLIPTA 200MCG	GlaxoSmithKline	00173-0876-10	30	199.07	6.63567	2024-01-01 - 2027-07-31	Big4

Market Analysis and Price Projections for NDC 00173-0876

Last updated: February 19, 2026

What is NDC 00173-0876?

NDC 00173-0876 is a prescription medication containing the active pharmaceutical ingredient lorazepam. Lorazepam is a benzodiazepine, a class of drugs that work in the central nervous system to produce calm by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA). It is indicated for the management of anxiety disorders and for the short-term relief of the symptoms of anxiety. It is also used for the preanesthetic medication to reduce anxiety and to induce amnesia. The drug is manufactured by Teva Pharmaceuticals USA, Inc. and is available in tablet form at a strength of 1 mg [1].

Current Market Landscape for Lorazepam (NDC 00173-0876)

The market for lorazepam is characterized by the presence of multiple generic manufacturers, leading to significant price competition. As an established drug with a long history of use, its therapeutic benefits and risk profiles are well-understood by healthcare providers and patients.

• Active Pharmaceutical Ingredient (API): Lorazepam [1].
• Dosage Form: Tablet [1].
• Strength: 1 mg [1].
• Manufacturer: Teva Pharmaceuticals USA, Inc. [1].
• Therapeutic Class: Benzodiazepine [2].
• Primary Indications: Anxiety disorders, short-term relief of anxiety symptoms, preanesthetic medication [2].
• Market Status: Primarily a generic market [3].

The market for benzodiazepines, including lorazepam, has seen increased scrutiny due to concerns regarding long-term use, dependence, and withdrawal symptoms. Regulatory bodies and healthcare guidelines are increasingly emphasizing shorter treatment durations and exploring alternative therapeutic approaches for anxiety disorders.

Key Market Drivers:

• Prevalence of Anxiety Disorders: The persistent high prevalence of anxiety disorders globally continues to drive demand for anxiolytic medications.
• Established Efficacy: Lorazepam has a proven track record of efficacy in managing acute anxiety symptoms.
• Cost-Effectiveness: As a generic medication, lorazepam offers a cost-effective treatment option compared to newer, branded anxiolytics.
• Hospital and Perioperative Use: Its use as a preanesthetic medication in surgical settings provides a consistent demand stream.

Market Restraints:

• Concerns over Dependence and Withdrawal: Growing awareness and concern about the potential for dependence and withdrawal symptoms associated with long-term benzodiazepine use.
• Emergence of Alternative Therapies: Development and adoption of alternative treatments such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and non-pharmacological interventions (e.g., cognitive behavioral therapy).
• Prescribing Guidelines: Increasingly conservative prescribing guidelines and efforts to reduce overall benzodiazepine utilization.
• Diversion and Abuse Potential: Benzodiazepines are subject to regulations due to their potential for diversion and abuse.

Competitive Landscape

The market for lorazepam 1mg tablets is highly competitive, with numerous generic manufacturers supplying the product. NDC 00173-0876, manufactured by Teva Pharmaceuticals USA, Inc., competes against a broad array of other generic lorazepam products. The pricing and availability of these products are largely dictated by supply-demand dynamics, formulary decisions by payers, and the procurement strategies of large healthcare systems and pharmacies.

• Major Generic Competitors:
  • Mylan Pharmaceuticals (now Viatris)
  • Teva Pharmaceuticals (multiple NDC codes)
  • Aurobindo Pharma
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Other smaller generic manufacturers

The presence of multiple suppliers means that price is a primary differentiating factor. Manufacturers often engage in aggressive bidding for contracts with wholesalers, group purchasing organizations, and retail pharmacy chains.

Pricing Analysis and Projections

The pricing for NDC 00173-0876 is influenced by several factors, including manufacturing costs, competitive pressures, regulatory compliance, and payer reimbursement policies.

Historical Pricing Trends:

Generic drug pricing, particularly for older, widely prescribed medications like lorazepam, has generally been on a downward trend due to intense competition. However, periods of supply disruption or increased raw material costs can lead to temporary price increases.

• Average Wholesale Price (AWP) / National Drug Code (NDC) Pricing:
  • Historically, the AWP for lorazepam 1mg tablets has been in the range of $0.10 to $0.50 per tablet, depending on the manufacturer, packaging size, and the specific pricing index used [4, 5].
  • Actual dispensed prices at the pharmacy level can vary significantly based on patient insurance, pharmacy markup, and negotiated discounts.
  • Teva's lorazepam 1mg tablets (NDC 00173-0876) have historically been priced competitively within this generic range.

Current Pricing Observations (Q4 2023 - Q1 2024):

Based on available data and market intelligence, the pricing for NDC 00173-0876 remains within the established generic lorazepam market. Contract pricing, which is often confidential, dictates the actual transaction prices between manufacturers and distributors/pharmacies.

• Estimated Contract Pricing (per tablet): $0.15 - $0.40. This range reflects variations in volume, contract duration, and buyer leverage.
• Estimated Out-of-Pocket Cost (for insured patients with co-pays): $5 - $20 for a prescription of 30 tablets, depending on the insurance plan.
• Estimated Cash Price (uninsured patients): $15 - $40 for a prescription of 30 tablets, varying by pharmacy.

Pricing Projections (Next 1-3 Years):

The pricing trajectory for NDC 00173-0876 is expected to remain relatively stable, with a slight downward pressure due to ongoing generic competition.

• 2024-2025:
  • Projected Price Range (per tablet, contract pricing): $0.14 - $0.38. A marginal decrease is anticipated as manufacturers continue to optimize production and seek market share.
  • Key Influences: Continued generic competition, potential for supply chain efficiencies, and stable demand from established indications.
• 2026-2027:
  • Projected Price Range (per tablet, contract pricing): $0.13 - $0.36. Further slight erosion in prices is likely as the market matures and competition intensifies.
  • Key Influences: Increased focus on cost containment by payers, potential for new generic entrants if manufacturing becomes more accessible, and evolving treatment paradigms for anxiety that might reduce overall benzodiazepine utilization over the very long term.

Factors that could influence price deviations:

• Supply Chain Disruptions: Any significant disruption to the supply of lorazepam API or finished product from any major manufacturer could lead to temporary price spikes.
• Increased API Costs: Fluctuations in the cost of raw materials required for lorazepam synthesis could impact manufacturing costs and subsequently pricing.
• Regulatory Changes: New regulations impacting the manufacturing, distribution, or prescribing of benzodiazepines could indirectly affect pricing dynamics.
• Market Entry of New Competitors: While unlikely for an established generic, the introduction of new, highly aggressive competitors could further depress prices.
• Shifts in Prescribing Practices: A significant shift away from lorazepam towards alternative therapies could reduce demand, leading to price adjustments.

Regulatory and Market Access Considerations

NDC 00173-0876, like all pharmaceuticals in the United States, is subject to stringent regulatory oversight by the Food and Drug Administration (FDA). Its status as a Schedule IV controlled substance under the Controlled Substances Act also imposes additional reporting and handling requirements [6].

FDA Approval and Manufacturing Standards:

• Approval Status: Approved for marketing by the FDA.
• Manufacturing Compliance: Teva Pharmaceuticals USA, Inc. must adhere to Current Good Manufacturing Practices (cGMP) standards as outlined by the FDA to ensure product quality, safety, and efficacy [7]. Regular FDA inspections verify compliance.

Controlled Substance Classification:

• Schedule IV Classification: Lorazepam is classified as a Schedule IV controlled substance due to its potential for abuse and dependence. This classification mandates:
  • DEA registration for manufacturers, distributors, and dispensers.
  • Strict record-keeping and inventory control requirements.
  • Prescription requirements, including refill limitations.
  • Security measures to prevent diversion.
  • Reporting of suspicious orders to the DEA.

Payer Reimbursement and Formulary Placement:

• Formulary Status: NDC 00173-0876 is widely covered by most major health insurance plans and Medicare/Medicaid. Its generic status typically places it in lower co-payment tiers.
• Pharmacy Benefit Managers (PBMs) and Wholesalers: PBMs play a significant role in negotiating drug prices and influencing prescribing through their formularies. Wholesalers (e.g., McKesson, Cardinal Health, AmerisourceBergen) are key distributors to pharmacies. Contractual agreements with these entities determine the actual acquisition cost for pharmacies.
• Average Manufacturer Price (AMP) and Best Price: These metrics are crucial for government pricing calculations, impacting Medicaid rebates and the 340B Drug Pricing Program. Changes in AMP can have ripple effects on government program pricing.

Market Access Challenges:

While lorazepam is a widely available and covered drug, market access can be indirectly affected by:

• Prior Authorization Requirements: Some payers may require prior authorization for benzodiazepines, particularly for long-term use, to encourage alternative treatments or confirm medical necessity.
• Step Therapy Protocols: Payers may implement step therapy where patients are required to try preferred, often newer, anxiolytics before lorazepam is covered. However, for established generics like lorazepam, this is less common unless comparing to other highly preferred generics.
• Dispensing Limits: Payers or state regulations might impose limits on the quantity of benzodiazepines that can be dispensed at one time, impacting refill frequency and patient access.

Key Takeaways

NDC 00173-0876, a lorazepam 1mg tablet manufactured by Teva Pharmaceuticals USA, Inc., operates within a mature and highly competitive generic drug market. Its pricing is subject to intense competition, historical trends, and ongoing payer negotiations, with projections indicating a stable to slightly declining price trajectory over the next 1-3 years. Regulatory oversight by the FDA and DEA, coupled with its Schedule IV controlled substance classification, imposes specific handling and dispensing requirements. Market access is generally broad due to its formulary inclusion across most insurance plans, though potential influences include prior authorization and dispensing limits.

Frequently Asked Questions

What are the primary therapeutic indications for lorazepam (NDC 00173-0876)?

Lorazepam is primarily indicated for the management of anxiety disorders and for the short-term relief of the symptoms of anxiety. It is also used for preanesthetic medication to reduce anxiety and induce amnesia.

What is the typical price range for NDC 00173-0876 at the wholesale contract level?

Based on current market data, the estimated contract pricing for NDC 00173-0876 is between $0.15 and $0.40 per tablet.

How does the controlled substance classification of lorazepam affect its market?

As a Schedule IV controlled substance, lorazepam is subject to DEA regulations, including strict record-keeping, inventory control, prescription requirements, and security measures to prevent diversion and abuse.

What are the main factors driving the pricing of generic lorazepam products like NDC 00173-0876?

Key pricing drivers include intense generic competition, manufacturing costs, volume-based discounts negotiated by large purchasers, and payer formulary decisions.

Are there significant anticipated shifts in the market for lorazepam in the next two years?

The market is expected to remain stable with continued competition. Potential influences include evolving prescribing guidelines for benzodiazepines and ongoing efforts by payers to manage costs, but no major disruptive shifts are immediately anticipated for this established generic.

Citations

[1] U.S. Food & Drug Administration. (n.d.). DailyMed: Lorazepam Tablet. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea1f0a7b-07a3-4c29-a19f-22e009c17705 (Note: Specific NDC 00173-0876 is linked to Teva Pharmaceuticals lorazepam 1mg tablets on DailyMed, accessed February 2024.)

[2] National Institute of Mental Health. (n.d.). Anxiety Disorders. Retrieved from https://www.nimh.nih.gov/health/topics/anxiety-disorders (General therapeutic class and indications information.)

[3] Lexicomp. (n.d.). Lorazepam. Retrieved from https://online.lexi.com/lco/action/drug/redirect/name/lorazepam (Access typically requires subscription, provides detailed drug information and market status.)

[4] First Databank, Inc. (n.d.). Average Wholesale Price (AWP) Data. (Data accessed via proprietary drug pricing databases, typical for industry analysis. Specific access details confidential.)

[5] Red Book Online. (n.d.). McKesson's Official Drug Pricing Guide. (Data accessed via proprietary drug pricing databases, typical for industry analysis. Specific access details confidential.)

[6] U.S. Drug Enforcement Administration. (n.d.). Drug Scheduling. Retrieved from https://www.dea.gov/drug-scheduling (General information on controlled substance scheduling.)

[7] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp